4D Molecular Therapeutics FDMT Collaboration And License Revenue — Revenue

Similar metrics at other companies

RXSTLicense And Collaboration Revenue — Revenue

$6.5M—

ABUSCollaborations and licenses — Revenue

$204K-84.5%

IRWDCollaborative Arrangement Collaboration And License Agreements — Revenue

$397K-7.2%

PTCTCollaboration And License Revenue — Revenue

$143K-100.0%

KURALicense And Collaboration Revenue — Revenue

$12.5M-11.4%

ABUSRevenue from collaborations and licenses — Revenue

$178.74M+21,912%

FAQ

What is 4D Molecular Therapeutics's collaboration and license revenue — revenue?

4D Molecular Therapeutics (FDMT) reported collaboration and license revenue — revenue of $3.05M in Q1 2026.

How has 4D Molecular Therapeutics's collaboration and license revenue — revenue changed year-over-year?

4D Molecular Therapeutics's collaboration and license revenue — revenue increased by 21664.3% year-over-year, from $14K to $3.05M.

What is the long-term trend for 4D Molecular Therapeutics's collaboration and license revenue — revenue?

Over 4 years (2021 to 2025), 4D Molecular Therapeutics's collaboration and license revenue — revenue has grown at a 47.4% compound annual growth rate (CAGR), from $18.04M to $85.21M.

What does collaboration and license revenue — revenue mean?

This metric represents the total revenue recognized from strategic partnerships, research collaborations, and the licensing of proprietary technology platforms or intellectual property to third parties. It reflects the company's ability to monetize its research and development pipeline by leveraging external capital and expertise to advance clinical-stage therapeutic candidates. Fluctuations in this metric often indicate the timing of milestone achievements, upfront payments, or the successful execution of commercialization agreements within the biotechnology sector.